Efeitos farmacológicos da hidroxicloroquina em pacientes com COVID-19: Revisão sistemática da literatura
DOI:
https://doi.org/10.33448/rsd-v10i8.17193Palavras-chave:
Hidroxicloroquina; Covid19; Coronavírus; Tratamento.Resumo
Um surto do novo coronavírus (COVID-19) teve início em dezembro de 2019 e se espalhou pela China, alastrando-se pelo mundo em pouco tempo, o que requer pesquisas imediatas para seu tratamento. Assim, o uso de cloroquina (CQ) e hidroxicloroquina (HCQ) tem despertado interesse no COVID-19. Esta revisão sistemática segue os itens de relatório indicados para revisões sistemáticas e Diretrizes de Meta-Análise (PRISMA). Os descritores selecionados foram: “SARS-CoV-2”, “COVID-19”, “Hydroxychloroquine” e “Chloroquine” e incluídos nas bases de dados Science Direct, United States National Library of Medicine (PubMed), informações bibliográficas latino-americanas em saúde ciências (LILACS), Scientific Electronic Library Online (SciELO) e Web of Science para busca de estudos. Após a triagem, um total de 6.339 estudos foram encontrados. Após a leitura e aplicação dos critérios de elegibilidade, foram selecionados 8 artigos para elaboração dos resultados desta revisão. Os resultados dos estudos mostraram que o uso de HCQ apresenta desfechos sem melhora significativa do quadro clínico, incluindo associação com eventos adversos (inclusive graves) em pacientes com COVID-19. Assim, os ensaios clínicos randomizados não forneceram evidências de eficácia da HCQ em pacientes com COVID-19, mostrando que a HCQ não é significativamente eficaz e apresenta resultados negativos em relação à sua segurança para pacientes com COVID-19.
Referências
Barbosa, J., Kaitis, D., Freedman, R., Le, K., & Lin, X. (2020). Clinical outcomes of hydroxychloroquine in hospitalized patients with COVID-19: a quasi-randomized comparative study. N Engl J Med, 1, 8882.
Borba, M., de Almeida Val, F., Sampaio, V. S., Alexandre, M. A., Melo, G. C., Brito, M., & Lacerda, M. (2020). Chloroquine diphosphate in two different dosages as adjunctive therapy of hospitalized patients with severe respiratory syndrome in the context of coronavirus (SARS-CoV-2) infection: Preliminary safety results of a randomized, double-blinded, phase IIb clinical trial (CloroCovid-19 Study). MedRxiv.
Bosseboeuf, E., Aubry, M., Nhan, T., De Pina, J. J., Rolain, J. M., Raoult, D., & Musso, D. (2018). Azithromycin inhibits the replication of Zika virus. J Antivir Antiretrovir, 10(1), 6-11.
Boulware, D. R., Pullen, M. F., Bangdiwala, A. S., Pastick, K. A., Lofgren, S. M., Okafor, E. C., & Hullsiek, K. H. (2020). A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. New England Journal of Medicine, 383(6), 517-525.
Campbell, M., McKenzie, J. E., Sowden, A., Katikireddi, S. V., Brennan, S. E., Ellis, S., HartmannBoyce, J., Ryan, R., Shepperd, S., Thomas, J., et al. (2020). Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline. BMJ 368, l6890.
Channappanavar, R., & Perlman, S. (2017). Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. In Seminars in immunopathology (39, 529-539). Springer Berlin Heidelberg.
Chen, J., Liu, D., Liu, L., Liu, P., Xu, Q., Xia, L., & Lu, H. (2020). A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19). Journal of Zhejiang University (Medical Science), 49(1), 0-0.
Colson, P., Rolain, J. M., Lagier, J. C., Brouqui, P., & Raoult, D. (2020). Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents, 55(4), 105932.
Cui, J., Li, F., & Shi, Z. L. (2019). Origin and evolution of pathogenic coronaviruses. Nature Reviews Microbiology, 17(3), 181-192.
Donnelly, C. A., Ghani, A. C., Leung, G. M., Hedley, A. J., Fraser, C., Riley, S., & Anderson, R. M. (2003). Epidemiological determinants of spread of causal agent of severe acute respiratory syndrome in Hong Kong. The Lancet, 361(9371), 1761-1766.
Fantini, J., Di Scala, C., Chahinian, H., & Yahi, N. (2020). Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection. International journal of antimicrobial agents, 55(5), 105960.
Fiolet, T., Guihur, A., Rebeaud, M. E., Mulot, M., Peiffer-Smadja, N., & Mahamat-Saleh, Y. (2021). Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis. Clinical microbiology and infection, 27(1), 19-27.
Forni, D., Cagliani, R., Clerici, M., & Sironi, M. (2017). Molecular evolution of human coronavirus genomes. Trends in microbiology, 25(1), 35-48.
Fteiha, B., Karameh, H., Kurd, R., Ziff‐Werman, B., Feldman, I., Bnaya, A., & Ben‐Chetrit, E. (2020). QTc prolongation among hydroxychloroquine sulfate‐treated COVID‐19 patients: An observational study. International Journal of Clinical Practice, e13767.
Gabriels, J., Saleh, M., Chang, D., & Epstein, L. M. (2020). Inpatient use of mobile continuous telemetry for COVID-19 patients treated with hydroxychloroquine and azithromycin. HeartRhythm Case Reports, 6(5), 241-243.
Gautret, P., Lagier, J. C., Parola, P., Meddeb, L., Mailhe, M., Doudier, B., & Raoult, D. (2020). Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. International journal of antimicrobial agents, 56(1), 105949.
Goel, P., & Gerriets, V. (2019). Chloroquine.
Gu, J., Gong, E., Zhang, B., Zheng, J., Gao, Z., Zhong, Y., & Leong, A. S. Y. (2005). Multiple organ infection and the pathogenesis of SARS. Journal of Experimental Medicine, 202(3), 415-424.
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., & Pöhlmann, S. (2020). SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell, 181(2), 271-280.
Hu, T. Y., Frieman, M., & Wolfram, J. (2020). Insights from nanomedicine into chloroquine efficacy against COVID-19. Nature nanotechnology, 15(4), 247-249.
Huang, M., Tang, T., Pang, P., Li, M., Ma, R., Lu, J., & Shan, H. (2020). Treating COVID-19 with chloroquine. Journal of molecular cell biology, 12(4), 322-325.
Hui, D. S., Azhar, E. I., Madani, T. A., Ntoumi, F., Kock, R., Dar, O., & Petersen, E. (2020). The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health—The latest 2019 novel coronavirus outbreak in Wuhan, China. International journal of infectious diseases, 91, 264-266.
Ip, A., Ahn, J., Zhou, Y., Goy, A. H., Hansen, E., Pecora, A. L., & Goldberg, S. L. (2021). Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: a multi-center observational study. BMC Infectious Diseases, 21(1), 1-12.
Iwata-Yoshikawa, N., Okamura, T., Shimizu, Y., Hasegawa, H., Takeda, M., & Nagata, N. (2019). TMPRSS2 contributes to virus spread and immunopathology in the airways of murine models after coronavirus infection. Journal of virology, 93(6), e01815-18.
Jia, H. P., Look, D. C., Shi, L., Hickey, M., Pewe, L., Netland, J., & McCray Jr, P. B. (2005). ACE2 receptor expression and severe acute respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia. Journal of virology, 79(23), 14614-14621.
Jie, Z., He, H., Xi, H., & Zhi, Z. (2020). Multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia. Expert Consensus on Chloroquine Phosphate for the Treatment of Novel Coronavirus Pneumonia [in Chinese], 10, 1001-0939.
Keyaerts, E., Vijgen, L., Maes, P., Neyts, J., & Van Ranst, M. (2004). In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. Biochemical and biophysical research communications, 323(1), 264-268.
Kim, T. S., Heinlein, C., Hackman, R. C., & Nelson, P. S. (2006). Phenotypic analysis of mice lacking the Tmprss2-encoded protease. Molecular and cellular biology, 26(3), 965-975.
Kupferschmidt, K., & Cohen, J. (2020). Race to find COVID-19 treatments accelerates.
Li, W., Moore, M. J., Vasilieva, N., Sui, J., Wong, S. K., Berne, M. A., & Farzan, M. (2003). Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature, 426(6965), 450-454.
Liu, J., Cao, R., Xu, M., Wang, X., Zhang, H., Hu, H., ... & Wang, M. (2020). Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell discovery, 6(1), 1-4.
Lu, H. (2020). Drug treatment options for the 2019-new coronavirus (2019-nCoV). Bioscience trends, 14(1), 69-71.
Madrid, P. B., Panchal, R. G., Warren, T. K., Shurtleff, A. C., Endsley, A. N., Green, C. E., & Tanga, M. J. (2015). Evaluation of Ebola virus inhibitors for drug repurposing. ACS infectious diseases, 1(7), 317-326.
Marmor, M. F. (2020). COVID-19 and chloroquine/hydroxychloroquine: is there ophthalmological concern?. American journal of ophthalmology, 216, A1-A2.
Matsuyama, S., Nagata, N., Shirato, K., Kawase, M., Takeda, M., & Taguchi, F. (2010). Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2. Journal of virology, 84(24), 12658-12664.
Menachery, V. D., Dinnon III, K. H., Yount Jr, B. L., McAnarney, E. T., Gralinski, L. E., Hale, A., & Baric, R. S. (2020). Trypsin treatment unlocks barrier for zoonotic bat coronavirus infection. Journal of virology, 94(5), e01774-19.
Millet, J. K., & Whittaker, G. R. (2014). Host cell entry of Middle East respiratory syndrome coronavirus after two-step, furin-mediated activation of the spike protein. Proceedings of the National Academy of Sciences, 111(42), 15214-15219.
Mitra, R. L., Greenstein, S. A., & Epstein, L. M. (2020). An algorithm for managing QT prolongation in coronavirus disease 2019 (COVID-19) patients treated with either chloroquine or hydroxychloroquine in conjunction with azithromycin: Possible benefits of intravenous lidocaine. HeartRhythm case reports, 6(5), 244.
Page, M.J., McKenzie, J.E., Bossuyt, P.M., Boutron, I., Hoffmann, T.C., Mulrow, C.D., Shamseer, L., Tetzlaff, J.M., Akl, E.A., Brennan, S.E., et al. (2021). The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. PLOS Medicine 18, e1003583.
Proano, C., & Kimball, G. P. (2019). Hydroxychloroquine retinal toxicity. New England Journal of Medicine, 380(17).
Retallack, H., Di Lullo, E., Arias, C., Knopp, K. A., Laurie, M. T., Sandoval-Espinosa, C., & DeRisi, J. L. (2016). Zika virus cell tropism in the developing human brain and inhibition by azithromycin. Proceedings of the National Academy of Sciences, 113(50), 14408-14413.
Riou, J., & Althaus, C. L. (2020). Pattern of early human-to-human transmission of Wuhan 2019 novel coronavirus (2019-nCoV), December 2019 to January 2020. Eurosurveillance, 25(4), 2000058.
Rodriguez-Morales, A. J., Bonilla-Aldana, D. K., Balbin-Ramon, G. J., Rabaan, A. A., Sah, R., Paniz-Mondolfi, A., & Esposito, S. (2020). History is repeating itself: Probable zoonotic spillover as the cause of the 2019 novel Coronavirus Epidemic. Infez Med, 28(1), 3-5.
Schrezenmeier, E., & Dörner, T. (2020). Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nature Reviews Rheumatology, 16(3), 155-166.
Self, W. H., Semler, M. W., Leither, L. M., Casey, J. D., Angus, D. C., Brower, R. G., & Brown, S. M. (2020). Effect of hydroxychloroquine on clinical status at 14 days in hospitalized patients with COVID-19: a randomized clinical trial. JAMA, 324(21), 2165-2176.
Shulla, A., Heald-Sargent, T., Subramanya, G., Zhao, J., Perlman, S., & Gallagher, T. (2010). A transmembrane serine protease is linked to the SARS coronavirus receptor and activates virus entry. Journal of Virology.
Skipper, C. P., Pastick, K. A., Engen, N. W., Bangdiwala, A. S., Abassi, M., Lofgren, S. M., & Boulware, D. R. (2020). Hydroxychloroquine in nonhospitalized adults with early COVID-19: a randomized trial. Annals of internal medicine, 173(8), 623-631.
Sogut, O., Can, M. M., Guven, R., Kaplan, O., Ergenc, H., Umit, T. B., ... & Cakmak, S. (2021). Safety and efficacy of hydroxychloroquine in 152 outpatients with confirmed COVID-19: a pilot observational study. The American journal of emergency medicine, 40, 41-46.
Van Den Brand, J. M. A., Haagmans, B. L., van Riel, D., Osterhaus, A. D. M. E., & Kuiken, T. (2014). The pathology and pathogenesis of experimental severe acute respiratory syndrome and influenza in animal models. Journal of comparative pathology, 151(1), 83-112.
Vincent, M. J., Bergeron, E., Benjannet, S., Erickson, B. R., Rollin, P. E., Ksiazek, T. G., & Nichol, S. T. (2005). Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virology journal, 2(1), 1-10.
Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., & Xiao, G. (2020). Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell research, 30(3), 269-271.
World Health Organization. World health statistics 2021. World Health Organization, 2021. https://www.who.int/emergencies/diseases/novel-coronavirus-2019 (accessed on 20 05 2021).
Xia, W., Shao, J., Guo, Y., Peng, X., Li, Z., & Hu, D. (2020). Clinical and CT features in pediatric patients with COVID‐19 infection: different points from adults. Pediatric pulmonology, 55(5), 1169-1174.
Yang, Y., Du, L., Liu, C., Wang, L., Ma, C., Tang, J., & Li, F. (2014). Receptor usage and cell entry of bat coronavirus HKU4 provide insight into bat-to-human transmission of MERS coronavirus. Proceedings of the National Academy of Sciences, 111(34), 12516-12521.
Yazdany, J., & Kim, A. H. (2020). Use of hydroxychloroquine and chloroquine during the COVID-19 pandemic: what every clinician should know.
Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., & Tan, W. (2020). A novel coronavirus from patients with pneumonia in China, 2019. New England journal of medicine.
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Copyright (c) 2021 Francisco Emanoel Alves de Araújo; João Matheus Caé da Rocha; Lucas Emmanuel Rocha de Moura Marques; Kellyson Lopes da Silva Macedo; Paloma Katlheen Moura Melo; Gabriella Mendes Duarte; Francisco Irochima Pinheiro; Fausto Pierdoná Guzen
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
Autores que publicam nesta revista concordam com os seguintes termos:
1) Autores mantém os direitos autorais e concedem à revista o direito de primeira publicação, com o trabalho simultaneamente licenciado sob a Licença Creative Commons Attribution que permite o compartilhamento do trabalho com reconhecimento da autoria e publicação inicial nesta revista.
2) Autores têm autorização para assumir contratos adicionais separadamente, para distribuição não-exclusiva da versão do trabalho publicada nesta revista (ex.: publicar em repositório institucional ou como capítulo de livro), com reconhecimento de autoria e publicação inicial nesta revista.
3) Autores têm permissão e são estimulados a publicar e distribuir seu trabalho online (ex.: em repositórios institucionais ou na sua página pessoal) a qualquer ponto antes ou durante o processo editorial, já que isso pode gerar alterações produtivas, bem como aumentar o impacto e a citação do trabalho publicado.
